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Background: The Saphenous Vein (SVG) is used in over 80% of coronary artery bypass procedures (CABG) and SVG
patency is the Achilles heel of CABG. To address this issue, the eSVS Mesh®, an external Nitinol knitted mesh, fitted
like a sleeve over the vein graft preventing over expansion in the high pressure arterial system, has been introduced
to improve disease management. Patency data is limited. The objective of this retrospective study is to report
patency rates (>3 months) in patients having external mesh support as part of CABG.
Methods: From October 25, 2010 through February 13, 2012, 21 patients had external mesh support of SVG grafts in
addition to internal thoracic artery grafting to the Anterior Descending artery. Patients were invited to return for
patency evaluation using Computerized Tomographic angiography (CTA) an average of 7.2 months post-operative
(R = 3-14 months).
Results: 21 male patients (age 57 +/− 9 years) underwent on-pump surgery. The eSVS Mesh was successfully placed
on all SVGs. All grafts were determined patent intra-operative by transit time Doppler measurement and there were
no operative revisions. There was no operative mortality. 12 of the 21 contacted patients returned for CTA, 8
non-returning patients contacted were alive and asymptomatic but refused to return due to travel restrictions
or cost. One patient was lost to follow up. 11 returning patients underwent CTA. One patient was excluded
(asymptomatic) due to elevated creatinine. Of the 23 anastomoses in 11 patients (Average: 2.09 grafts/patient) using
SVG available for examination, 21 were patent (92%).
Conclusions: In this retrospective non-randomized experience, the external mesh supported grafts displayed excellent
intermediate patency.
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Coronary Artery Bypass Grafting (CABG) has been
shown to prolong life expectancy in patients with left
main, triple vessel and/or single vessel disease with
stenosis of the proximal left anterior descending artery
and in those with triple vessel disease and depressed
left ventricular function as well as diabetic patients
[1-6]. Complete revascularization has long been a hall-
mark advantage of surgical coronary revascularization
[7]. In spite of the fact that the use of bilateral internal
thoracic arteries have a proven survival and decreased* Correspondence: remery1513@aol.com
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unless otherwise stated.major adverse cardiac and cerebral events rate at out to
thirty years post-CABG, the use of the saphenous vein
is necessary in over 80% of surgical cases to complete
revascularization [1,8,9]. The Achilles heel with the sa-
phenous vein over the long term is its lower patency
rate as compared to arterial grafting [10,11]. SVG loss
can be up to 50% in 10 years and is related to placing
the saphenous vein, normally subject to lower venous
pressures into the arterial system.
With the lack of muscular walls seen in arteries, when
placed under arterial pressure, the vein dilates. Because
of the acute impact of arterial pressure, damage to the
endothelium can occur, resulting in the thrombus for-
mation of and subsequent lipid deposition. Smoothtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Demographics on patients have eSVS Mesh
supported saphenous vein graft, returning for angiography
7.2 months post-operative coronary artery bypass
Baseline history Mean or % of subject
(N = 12)




Previous CABG 8% (1)





CAD in 1° Relative 83% (10)
NYHA Class
No/Unknown 42% (5)
Class I 8% (1)
Class II 17% (2)
Class III 25% (3)
Class IV 8% (1)
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wall and migrate to the intimal surface a process known
as neointimal hyperplasia. The resulting build up of
smooth muscle cells secrete inflammatory and growth
factors leading to graft stenosis and ultimate failure [12].
Further, compared to coronary arteries, saphenous veins
have a larger luminal diameter resulting in a vein graft
to coronary artery mismatch creating blood flow ab-
normalities including eddy currents and stasis. Experi-
mentally, downsizing the SVG with an external support
correlates with more arterial like healing and these grafts
develop less intimal hyperplasia [13,14]. With the con-
comitant resulting changes noted above, the major cause
of graft failure after one month is the development of
graft atherosclerotic disease and thrombosis. To address
these changes the eSVS Mesh (Kips Bay Medical Inc,
Minneapolis, MN) was developed.
The eSVS Mesh is an external support device that is
used to downsize the vein graft of up to 35%, making a
more appropriate vein to coronary artery match improv-
ing the pattern of blood flow. Also, importantly, because
of the constrictive external support, expansion of the
vein graft cannot occur to more than 8% of its diameter,
obviating endothelial injury with the exposure to acute
arterial pressure. Animal experimentation documented
improved graft healing in arterial like fashion with less
neointimal formation in supported grafts as opposed to
unsupported grafts [13-15]. A prospective randomized
“first in man” feasibility trial was conducted and at the
end of one year supported and unsupported grafts had
equivalent patency (FDA submission). CE Mark approval
was obtained in Europe. Post market studies are con-
tinuing. The object of the current study was to obtain
further data as to the intermediate term (>3 month) pa-
tency in patients receiving the eSVS Mesh external sup-
port graft as a part of their coronary revascularization
procedure.
Methods
The eSVS Mesh is an external support device available
in three sizes which accommodates veins 3.5 to 7.0 mm
when gently distended. The mesh is a highly flexible
Nitinol knitted, kink resistant prosthesis into which the
vein graft is inserted.
Included in the eSVS Mesh packet is a sizing tool to
measure the gently distended diameter of the vein and a
double wall thickness. Both of these measurements are
critical in choosing the appropriate size and application
of the eSVS Mesh. Veins larger than 7.0 mm and smaller
than 3.6 mm and/or are too thick to fit the double wall
measure should not be supported [16]. Due to radial
constriction of the SVG by the eSVS Mesh, larger veins
can be supported in smaller eSVS Mesh devices which
are available in 3.5, 4.0 and 4.5 mm sizes.The current study was conducted after ethics commit-
tee approval of the Medical Advisory Board and Board
of Directors at the American Hospital Dubai (AHD) and
individual patient written informed consent obtained.
The study was conducted in accordance with the ethical
principles and Declaration of Helsinki.
All patients having the eSVS Mesh as a portion of
their coronary bypass grafting from October 1, 2010
through February 28, 2012 were contacted after three
months or more following their procedure and were
asked to return for CTA the results of which were read
at AHD. The study is retrospective.
Twenty-one patients, all male, had the eSVS Mesh
used on all the saphenous veins as part of their CABG
over the study time frame. SVGs were harvested using
an open bridging technique and all procedures were
conducted on cardiopulmonary bypass with cardioplegic
arrest. The eSVS Mesh was able to be deployed in all
cases and there were no device related complications.
No sequential grafting was performed. The grafts were
determined to be patent intra-operatively using transit-
time Doppler flow measurement and no revisions neces-
sary. All patients were placed on aspirin and a statin, the
dosage depending on their cholesterol level, post-operative.
There was no operative mortality, re-exploration for bleed-
ing or sternal wound infection.
Successful contact was accomplished in 20 of 21 patients
(95%): All were alive and asymptomatic. One patient
Table 2 Sizes of eSVS Mesh used to support saphenous
vein grafts in patients returning for angiography
7.2 months post-operative coronary artery bypass
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phone refused to participate in CT angiography, seven
due to travel related restrictions or cost and one due to
hospital administrative conflict. Those having travel re-
strictions were from other countries in the Middle East.
Twelve patients (57%) returned for a follow-up. The
eSVS Mesh was used to support all of the 26 vein grafts
in these patients.
Numbers are expressed as mean +/− standard deviation.
Results
The mean age of the 12 patients returning for CTA, the
crux of this report, was 57 +/− 8.8 years and all wereFigure 1 Representative CT angiogram in a patient multiple patent sumale; the demographics of these patients is shown in
Table 1. Patients had 1 to 3 grafts all supported by eSVS
Mesh with a total of 26 saphenous vein grafts in addition
to internal mammary artery grafting to the anterior de-
scending coronary artery. The eSVS Mesh qualifying sizes
are shown in Table 2. There was an average of 2.2 SVG per
returning patient. Procedures concomitant to coronary by-
pass surgery were performed in 3 patients: one had throm-
boendarterectomy of the distal right coronary artery, one
repair of an ASD and one aortic root aneurysm reconstruc-
tion. The time interval from the operative procedure to
CTA was 7.2 +/− 3.7 (range = 3 to 14) months.
In the 12 patients, the eSVS Mesh supported graft was
placed in the right coronary position in 9 of 12 patients
(75%) and at least one supported graft was placed to the
circumflex system in 92% of patients (11 of 12). Three
patients had supported grafts placed to a diagonal
branch of the anterior descending system. All vein grafts
had only one distal anastomosis thus 35% of grafts were
placed to the right system (9 of 26) and 65% in the left
system (17 of 26). Patients were discharged at mean of
9.1 +/−3.9 days post-operative.pported saphenous vein grafts.
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which 23 Mesh supported SVG’s (2.09 grafts/patient)
were assessed. One patient having 3 supported grafts
was enrolled but was unable to have CT angiography due
to elevated Creatinine. He is alive and asymptomatic.
CTA (N = 11) revealed that 21 of the 23 grafts were pa-
tent (patency rate = 92%). There were 2 occluded grafts,
one to the right coronary artery and one to the circum-
flex artery. These CTAs were completed at 6 and 8 month
post-operative. A representative CT scan in a patient with
multiple patent supported grafts is shown in Figure 1,
and an example of a patient with an occluded graft is
shown in Figure 2. One patient had a stenosis of 60-70%
noted in the mid-portion of a graft. The LIMA graft to
the LAD was patent in all cases.
Discussion
Use of the saphenous vein in coronary bypass surgery is
necessary in over 80% of cases to assure completion of
the bypass graft procedure [7]. The use of the bilateralFigure 2 Representative CT angiogram in a patient with an occludedinternal mammary artery is an important aspect of cor-
onary bypass grafting to compete with stent graft place-
ment; however, saphenous vein grafting is still warranted
in the majority of cases [1,6,8,11]. Early saphenous vein
patency (<1 week) is substantively improved by anti-
platelet therapy delivered 1–6 hours post-operative and
combined with cholesterol lowering with statin therapy
improves patency to one year [17,18]. Beyond this, no
substantive impact has been made in preventing the devel-
opment of vein graft atherosclerosis or improving patency.
Patency of the SVG to one year is also less in smaller ves-
sels, younger age group patients and grafts to the circum-
flex and right coronary systems and to those vessels with
poor runoff [10,19]. No medical therapeutic or endothelial
antibody trial has improve patency beyond one year, thus
the concept of external vein support is appealing [20-22].
Saphenous vein graft patency at one year has been
reported to be as low as 75% and at ten years 50%
[11,18] over the subsequent 10 years there is a graft loss
of 1-2% per year due to the development of vein graftsupported saphenous vein graft.
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oped to address the lower patency saphenous vein. The
mesh graft supports and downsizes the SVG by up to
35% and prevents over expansion of the saphenous vein
to no more than 8% of its luminal diameter thus pre-
venting endothelial injury during acute exposure to ar-
terial pressure. Animal experiments have documented
arterial like healing of the supported grafts as compared
to unsupported grafts [13,14]. Early graft patency is
dependent on the quality of the vein harvested, diameter
of the coronary artery to which it is grafted, blood flow
through the graft and ejection fraction. Thus, early pa-
tency may not be impacted by the eSVS Mesh as the de-
vice is designed to prevent endothelial injury and vein
over distention, thus obviating the development of graft
atherosclerosis over time. Genoni found that early graft
patency is not negatively affected by use of the eSVS
Mesh, important data when using newly implantable
foreign material, assuring patient safety from poten-
tial device related complications [23].
Surgical technique can be applied using those methods
of any individual surgeon: Running versus interrupted
suture; proximal versus distal first; on pump or off pump
revascularization. Most importantly during construction
of the anastomosis, a cobra head must be created so the
graft is angulated properly both at the proximal and dis-
tal end [16]. Transit-Time Doppler Flow measurement is
recommended for intra-operative assessment of patency
as the external support mesh does not interfere with
Doppler signals [24]. Intermediate term patency data is,
however, limited.
A first in man pivotal study was performed as an inter-
national multi-center randomized trial with patients re-
ceiving grafts randomized to the right and left system
thus each patient served as their own control (personal
communication). This study showed equivalency in patency
between the supported and unsupported grafts. However,
several lessons were learned from this study which may fur-
ther improve the patency of supported grafts.
First, the smallest size, a 3 mm mesh was eliminated
as closure rate was increased in this group and secondly,
the need for an incision in the vein graft to create a cobra-
head anastomosis in completion of both the proximal and
the distal anastomosis is necessary to assure the each
graft lies properly without kinking. Creating a cobra head
for proper lie of the grafts is particularly important as
those grafts constructed without this technical step had
poor intermediate results [25]. Finally, accurate measure-
ment of the vein diameter and double wall thickness were
important in selecting appropriate veins to support.
Conclusion
The current study demonstrated excellent patency at
7.2 +/− 3.7 months of 92%.While there were no controlsand this post-market study was not randomized, com-
pared to the literature objective performance criteria,
graft patency at this time frame is improved [18,19]. The
eSVS Mesh thus does not negatively affect early graft pa-
tency, is adaptable to varying surgical techniques and
shows improvement in graft patency at the intermediate
term. Further prospective randomized trials are war-
ranted and longer term follow-up is necessary. Due to
graft support and improved flow characteristics, the de-
velopment of vein graft disease should be retarded and a
greater impact on long term as opposed to short term
patency expected. Studies are ongoing.
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